Sun Pharmaceutical Industries Ltd - 524715 - Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015
Sun Pharmaceutical reported the arrest of Independent Director Gautam Doshi. The company clarified the matter is not connected to its operations or Board processes, and no impact is currently envisaged.
Jun 14 2026 11:44:20
Sun Pharmaceutical Industries Ltd - 524715 - Intimation Of Record Date For The Purpose Of Final Dividend For FY 2025-26
Sun Pharma has fixed July 07, 2026, as the Record Date for a final dividend of ₹5 per equity share for FY 2025-26. Payment is slated for on or before August 07, 2026, post AGM approval.
Jun 12 2026 13:28:39
Sun Pharmaceutical Industries Ltd - 524715 - Corporate Action-Board to consider Dividend
Sun Pharma declared a final dividend of ₹5 per equity share for FY26. The record date for determining eligible shareholders is July 07, 2026, with payment expected by August 07, 2026, following AGM approval.
Jun 11 2026 22:56:47
Sun Pharmaceutical Industries Ltd - 524715 - Intimation Of 34Th Annual General Meeting And Record Date For Final Dividend And Connected Matters
Sun Pharma declared a final dividend of ₹5 per equity share for FY 2025-26. The record date for this dividend is set for July 07, 2026, with the payment scheduled on or before August 07, 2026, subject to shareholder approval at the upcoming AGM.
Jun 11 2026 14:31:46
Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Sun Pharmaceutical has scheduled three analyst and investor meetings in June 2026. These meetings include participation in the BofA India, Morgan Stanley India Investment Forum, and Citi India Conferences, all held in Mumbai. No unpublished price sensitive information will be disclosed.
May 27 2026 16:01:53
Sun Pharmaceutical Industries Ltd - 524715 - Additional Outcome Of The Board Meeting
Sun Pharma's Board of Directors approved the reclassification of certain promoter group individuals to the "Public" category. This reclassification is subject to approvals under SEBI Regulation 31A.
May 22 2026 18:17:30
Sun Pharmaceutical Industries Ltd - 524715 - Board Meeting Outcome for Recommendation Of Final Dividend
Sun Pharma's Board approved FY26 consolidated results: sales reached ₹58,220.1 cr (up 11.9% YoY) and net profit was ₹11,479.4 cr (up 5.0% YoY). The company also recommended a final dividend of ₹5 per share for FY26.
May 22 2026 15:02:33
Read More